Previous Close | 27.12 |
Open | 26.63 |
Bid | 11.08 x 1100 |
Ask | 0.00 x 800 |
Day's Range | 26.55 - 27.82 |
52 Week Range | 19.35 - 43.61 |
Volume | |
Avg. Volume | 382,348 |
Market Cap | 1.653B |
Beta (5Y Monthly) | 0.80 |
PE Ratio (TTM) | 15.60 |
EPS (TTM) | 1.78 |
Earnings Date | Aug 02, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 50.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for XNCR
MONROVIA, Calif., May 26, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the Phase 1 study evaluating XmAb®104, a PD-1 x ICOS bispecific antibody, in patients with advanced solid tumors (DUET-3). These results will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), during the poster
On a valuation basis, these small-cap stocks could be stocks to buy for long-term gains. Monro (MNRO): A good-quality stock you can buy now or wait for lower prices in. Jack in the Box (JACK): A well-known franchise with a low-priced valuation. Ultra Clean Holdings (UCTT): Its low valuation and growing earnings make it a stock to buy. Patrick Industries (PATK): It remains a stock to buy, even in this market environment. Xencor (XNCR): It had weak earnings, but watch this stock for a buying point
Xencor (NASDAQ:XNCR) has had a rough three months with its share price down 20%. But if you pay close attention, you...